The ANXA6 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 human lung adenocarcinoma cells, with disrupted ANXA6 expression. This polyclonal pool provides a heterogeneous loss-of-function model for studying ANXA6-dependent processes in a cancer-relevant background without clonal selection artifacts. CRISPR/Cas9-mediated gene disruption eliminates ANXA6??s functions in membrane trafficking, signal transduction, and cholesterol homeostasis.
The parental A-549 cell line, established from a lung adenocarcinoma of a 58-year-old male, serves as a widely used model of alveolar type II epithelial cells. These adherent epithelial cells are commonly employed in cancer biology and toxicology studies due to robust growth and well-characterized signaling pathways, making them a suitable host for investigating the tumor-suppressive role of ANXA6.
Annexin A6 (ANXA6) is a calcium-dependent phospholipid-binding protein that interacts with F-actin, S100A1, S100B, EGFR, H-Ras, p120GAP, and PKC??, modulating membrane organization and signaling. It functions as a negative regulator of the EGFR?CRas?CNF-??B axis: ANXA6 promotes EGFR downregulation and H-Ras inactivation via p120GAP, thereby limiting downstream MAPK and NF-??B (p65) signaling; absence of ANXA6 leads to sustained EGFR recycling, enhanced Ras/MAPK activity, and reduced I??B??-mediated NF-??B inhibition. ANXA6 is regulated by TP53 and calcium, and its downstream targets include cholesterol efflux mediators.
In A-549 polyclonal knockout cells, loss of ANXA6 removes a tumor-suppressive checkpoint, rendering cells more permissive to EGFR-driven proliferation, migration, and survival. Dysregulated cholesterol homeostasis further amplifies oncogenic signaling, mimicking aggressive lung adenocarcinoma features. This model enables dissection of the ANXA6?CH-Ras?CNF-??B interplay in an epithelial lung cancer context and exploration of therapeutic vulnerabilities from enhanced EGFR pathway activation.
These cells are suited for mechanistic assays such as western blotting and RT-qPCR for knockout confirmation, phospho-EGFR/ERK analysis to monitor MAPK signaling, co-immunoprecipitation of ANXA6 partners, and cholesterol efflux assays to assess lipid trafficking. Migration and invasion assays quantify metastatic behavior, and immunofluorescence, flow cytometry, or RNA-seq enable phenotypic and transcriptional profiling. This product supports research in lung cancer biology, drug resistance, and membrane biology. For further information, please contact Ascent Research.
